Evidence map›Paper›PMID 38971666›Full record

ArticleVaccine2024

Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].

Charlotte Laniece Delaunay, Aryse Melo, Marine Maurel, Clara Mazagatos, Luise Goerlitz, Joan O'Donnell, Beatrix Oroszi, Noémie Sève, Ana Paula Rodrigues, Iván Martínez-Baz and 21 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Charlotte Laniece DelaunayEpiconcept, Paris, France.
Aryse MeloNational Reference Laboratory for Influenza Virus and Other Respiratory Visuses, Infectious disease department - National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Marine MaurelEpiconcept, Paris, France.
Clara MazagatosNational Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain.
Luise GoerlitzRobert Koch institute, Berlin, Germany.
Joan O'DonnellHealth Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Beatrix OrosziNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Noémie SèveSorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Ana Paula RodriguesEpidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Iván Martínez-BazInstituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
Adam MeijerNational Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands.
Ivan MlinarićCroatian Institute of Public Health, Zagreb, Croatia.
Neus Latorre-MargalefPublic Health Agency of Sweden, Stockholm, Sweden.
Mihaela LazărCantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania.
Gloria Pérez-GimenoNational Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain.
Ralf DürrwaldNational Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
Charlene BennettUCD-National Virus Reference Laboratory University College Dublin, Dublin, Ireland.
Gergő TúriNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Marie-Anne Rameix-WeltiCentre National de Référence Virus des Infections Respiratoire (CNR VIR) Institut Pasteur Université Paris Cité, Paris, France; Institut Pasteur, Université Paris-Saclay, Université de Versailles St. Quentin, Université Paris Cité, UMR 1173 (2I), INSERM; Assistance Publique des Hôpitaux de Paris, Paris, France.
Raquel GuiomarNational Reference Laboratory for Influenza Virus and Other Respiratory Visuses, Infectious disease department - National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Jesús CastillaInstituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
Mariëtte HooiveldNivel, Utrecht, the Netherlands.
Sanja Kurečić FilipovićCroatian Institute of Public Health, Zagreb, Croatia.
Tove Samuelsson HageyPublic Health Agency of Sweden, Stockholm, Sweden.
Frederika DijkstraNational Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands.
Vitor BorgesBioinformatics Unit, Infectious Diseases Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Violeta Ramos MarínServicio de Epidemiología de la Consejería de Sanidad y Servicios Sociales de Ceuta, Ceuta, Spain.
Sabrina BacciEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Marlena KaczmarekEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Esther KisslingEpiconcept, Paris, France. Electronic address: e.kissling@epiconcept.fr.
European primary care VE group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38971666
PMCPMC11413480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.